Introduction
Methods
Sample and procedure
Rehabilitation program
Assessment instruments
Statistical analysis
Results
Patient characteristics
Characteristics | Total sample n = 939
n (%) | |
---|---|---|
Mean age (years± SD) | 58.6 (11.9), range:19–88 | |
Sex
| ||
Women (%) | 562 | (59.9) |
Men (%) | 377 | (40.1) |
Cancer sites
| ||
Breast cancer | 277 | (29.5) |
Hemato-oncological malignancy | 99 | (10.5) |
Colorectal cancer | 94 | (10.0) |
Head and neck cancer | 62 | (6.6) |
Prostate cancer (including penis and testes) | 57 | (6.1) |
Gastric cancer (including esophagus) | 52 | (5.5) |
Gynecological cancer | 44 | (4.7) |
Lung cancer | 43 | (4.6) |
Pancreatic cancer (including liver and gall bladder) | 34 | (3.6) |
Urinary organs | 34 | (3.6) |
Brain cancer | 14 | (1.5) |
Others | 68 | (7.2) |
Missing data | 61 | (6.5) |
HADS total score
| ||
Mean (SD) | 11.9 | 7.2 |
Psychotherapeutic pretreatment
| ||
Yes | 204 | (21.7) |
No | 726 | (77.3) |
Missing | 9 | (1.0) |
Preference for psycho-oncological focus
| ||
Yes | 453 | (48.2) |
No | 477 | (50.8) |
Missing | 9 | (1.0) |
Preferred psycho-oncological focus
| ||
Sexual psychology | 49 | (10.8) |
Existential analysis | 130 | (28.7) |
Biofeedback | 99 | (21.9) |
No preference | 127 | (28.0) |
Missing | 48 | (10.6) |
Treatment | Treatment frequency per patient | |||
---|---|---|---|---|
n
| (%) |
Median
|
IQR
| |
Physiotherapy/physical therapya
| 905 | (96.4) | 34 | 23–30 |
Health psychological counseling (group, 60 min.) | 904 | (96.3) | 1 | 1–1 |
Nutrition counseling | 901 | (96.0) | 2 | 1–3 |
Psycho-oncology (single, 25 min.) | 877 | (93.4) | 5 | 4–6 |
Massage/lymph drainage | 855 | (91.1) | 5 | 4–6 |
Thermotherapy | 791 | (84.2) | 6 | 4–7 |
Hydrogymnastics | 445 | (47.4) | 4 | 3–5 |
Self-help training | 412 | (43.9) | 3 | 2–3 |
Creativity training | 403 | (42.9) | 5 | 3–6 |
Electrotherapy | 383 | (40.8) | 6 | 4–8 |
Social counseling | 330 | (35.1) | 1 | 1–1 |
Biofeedback/relaxation exercise | 141 | (15.0) | 3 | 3–4 |
Ultrasonic therapy | 37 | (3.9) | 4 | 3–6 |
Improvement of HRQOL and psychological distress after rehabilitation
Study sample | Reference value | |||||
---|---|---|---|---|---|---|
T0 | T1 | Mean difference | ||||
Mean (SD) | Mean (SD) | Mean (SD) | (T1-T0) | ES |
p value | |
HADS
| ||||||
Anxiety | 6.1 (3.9)* | 4.2 (3.3)* | 4.7 (3.5) |
1.9
| 0.49 | <0.001 |
Depression | 5.6 (4.0)* | 3.4 (3.2)* | 4.8 (4.0) |
2.2
| 0.56 | <0.001 |
QLQ-C30 functioning
| ||||||
Physical functioning | 72.3 (21.0)* | 79.8 (19.6)* | 92.2 (15.1) |
7.5
| 0.36 | <0.001 |
Role functioning | 58.0 (31.0)* | 73.0 (26.4)* | 90.4 (20.2) |
15.0
| 0.48 | <0.001 |
Social functioning | 58.8 (30.7)* | 75.9 (25.8)* | 93.4 (17.2) |
17.1
| 0.56 | <0.001 |
Emotional functioning | 58.7 (25.6)* | 78.7 (21.3)* | 83.5 (19.7) |
20.1
| 0.78 | <0.001 |
Cognitive functioning | 72.8 (27.3)* | 78.6 (23.8)* | 93.5 (14.5) |
5.8
| 0.21 | <0.001 |
Global quality of life
| 58.6 (20.3)* | 74.2 (17.6)* | 75.0 (19.6) |
15.6
| 0.76 | <0.001 |
QLQ-C30 symptoms
| ||||||
Fatigue | 53.0 (26.5)* | 35.8 (23.5)* | 15.5 (21.6) |
17.2
| 0.65 | <0.001 |
Nausea/vomiting | 13.4 (22.4)* | 7.1 (17.2)* | 2.2 (8.9) |
6.3
| 0.28 | 0.17 |
Pain | 40.2 (29.3)* | 27.5 (26.4)* | 16.7 (24.2) |
12.7
| 0.43 | <0.001 |
Dyspnea | 33.8 (32.7)* | 29.3 (27.5)* | 7.5 (19.3) | 4.5 | 0.13 | 0.04 |
Insomnia | 46.3 (33.9)* | 36.7 (32.3)* | 12.4 (23.3) |
9.6
| 0.28 | <0.001 |
Appetite loss | 26.2 (33.2)* | 14.2 (26.2)* | 3.8 (13.3) |
12.0
| 0.36 | <0.001 |
Constipation | 20.7 (31.3)* | 11.5 (24.2)* | 2.2 (10.3) |
9.2
| 0.29 | <0.001 |
Diarrhea | 17.2 (27.7)* | 11.5 (22.8)* | 2.5 (11.6) |
5.7
| 0.21 | <0.001 |
Financial difficulties | 30.0 (34.0)* | 20.7 (29.8)* | 4.8 (16.6) |
9.3
| 0.27 | 0.001 |
T0 | T1 | ||||
---|---|---|---|---|---|
N
| (%) |
N
| % |
p-value | |
HADS-A
| |||||
Non-cases (≤7) | 624 | (66.8) | 790 | (84.1) | <0.001 |
Doubtful cases (8–10) | 178 | (19.1) | 108 | (11.5) | |
Clinical cases (≥11) | 132 | (14.1) | 38 | (4.0) | |
HADS-D
| |||||
Non-cases (≤7) | 648 | (69.3) | 837 | (89.5) | <0.001 |
Doubtful cases (8–10) | 158 | (16.9) | 63 | (6.7) | |
Clinical cases (≥11) | 129 | (13.8) | 35 | (3.7) |